Normal view MARC view ISBD view

Advances in the molecular biology of erythrocyte antigens. [electronic resource]

By:

Tanner, M J

Producer: 19980114Description: 139-45 p. digitalISSN:

1065-6251

Subject(s):

Online resources:

Available from publisher's website

In: Current opinion in hematology vol. 2

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

No physical items for this record

Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review

There are no comments on this title.

to post a comment.

Back to results

1 Analgesic effects of β-phenylethylamine and various methylated derivatives in mice.
by Mosnaim, Aron D
2 Behavioral effects of β-phenylethylamine and various monomethylated and monohalogenated analogs in mice are mediated by catecholaminergic mechanisms.
by Mosnaim, Aron D
3 The Utility of Impulsive Bias and Altered Decision Making as Predictors of Drug Efficacy and Target Selection: Rethinking Behavioral Screening for Antidepressant Drugs.
by Marek, Gerard J
4 Acute nicotine and phencyclidine increase locomotor activity of the guinea pig with attenuated potencies relative to their effects on rat or mouse.
by Simmons, Mark A
5 Drug Tolerance: A Known Unknown in Translational Neuroscience.
by Bespalov, Anton
6 Rat brain-uptake index for phenylethylamine and various monomethylated derivatives.
by Mosnaim, Aron D
7 β-Phenylethylamine and various monomethylated and para-halogenated analogs. Acute toxicity studies in mice.
by Mosnaim, Aron D
8 A retrospective evaluation of species-specific sensitivity for neurological signs in toxicological studies: Is the dog more sensitive than the non-human primate?
by Backes, Kathrin
9 Abuse liability assessment for biologic drugs - All molecules are not created equal.
by de Zafra, Christina L Zuch
10 Synthesis of novel quinolone and quinoline-2-carboxylic acid (4-morpholin-4-yl-phenyl)amides: a late-stage diversification approach to potent 5HT1B antagonists.
by Horchler, Carey L
11 Preclinical abuse liability assessment of ABT-126, an agonist at the α7 nicotinic acetylcholine receptor (nAChR).
by Hudzik, Thomas J
12 Mechanistic investigation of N,N-diethyl-4-(phenyl-piperidin-4-ylidenemethyl)-benzamide-induced insulin depletion in the rat and RINm5F cells.
by Otieno, Monicah A
13 Assessment of the abuse liability of ABT-288, a novel histamine H₃ receptor antagonist.
by Hudzik, Thomas J
14 4-Piperidin-4-ylidenemethyl-benzamides as δ-opioid receptor agonists for CNS indications: identifying clinical candidates.
by Dantzman, Cathy L
15 Multiparameter exploration of piperazine derivatives as δ-opioid receptor agonists for CNS indications.
by McCauley, John P
16 A randomized, placebo-controlled pilot trial of the delta opioid receptor agonist AZD2327 in anxious depression.
by Richards, Erica M
17 Translational Biomarkers of Neurotoxicity: A Health and Environmental Sciences Institute Perspective on the Way Forward.
by Roberts, Ruth A